What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

TY - JOUR

T1 - What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021

AU - Turco, Fabio

AU - Armstrong, Andrew

AU - Attard, Gerhardt

AU - Beer, Tomasz M

AU - Beltran, Himisha

AU - Bjartell, Anders

AU - Bossi, Alberto

AU - Briganti, Alberto

AU - Bristow, Rob G

AU - Bulbul, Muhammad

AU - Caffo, Orazio

AU - Chi, Kim N

AU - Clarke, Caroline

AU - Clarke, Noel

AU - Davis, Ian D

AU - de Bono, Johann

AU - Duran, Ignacio

AU - Eeles, Ros

AU - Efstathiou, Eleni

AU - Efstathiou, Jason

AU - Evans, Christopher P

AU - Fanti, Stefano

AU - Feng, Felix Y

AU - Fizazi, Karim

AU - Frydenberg, Mark

AU - George, Dan

AU - Gleave, Martin

AU - Halabi, Susan

AU - Heinrich, Daniel

AU - Higano, Celestia

AU - Hofman, Michael S

AU - Hussain, Maha

AU - James, Nicholas

AU - Jones, Rob

AU - Kanesvaran, Ravindran

AU - Khauli, Raja B

AU - Klotz, Laurence

AU - Leibowitz, Raya

AU - Logothetis, Christopher

AU - Maluf, Fernando

AU - Millman, Robin

AU - Morgans, Alicia K

AU - Morris, Michael J

AU - Mottet, Nicolas

AU - Mrabti, Hind

AU - Murphy, Declan G

AU - Murthy, Vedang

AU - Oh, William K

AU - Ekeke Onyeanunam, Ngozi

AU - Ost, Piet

AU - O'Sullivan, Joe M

AU - Padhani, Anwar R

AU - Parker, Christopher

AU - Poon, Darren M C

AU - Pritchard, Colin C

AU - Rabah, Danny M

AU - Rathkopf, Dana

AU - Reiter, Robert E

AU - Rubin, Mark

AU - Ryan, Charles J

AU - Saad, Fred

AU - Pablo Sade, Juan

AU - Sartor, Oliver

AU - Scher, Howard I

AU - Shore, Neal

AU - Skoneczna, Iwona

AU - Small, Eric

AU - Smith, Matthew

AU - Soule, Howard

AU - Spratt, Daniel

AU - Sternberg, Cora N

AU - Suzuki, Hiroyoshi

AU - Sweeney, Christopher

AU - Sydes, Matthew

AU - Taplin, Mary-Ellen

AU - Tilki, Derya

AU - Tombal, Bertrand

AU - Türkeri, Levent

AU - Uemura, Hiroji

AU - Uemura, Hirotsugu

AU - van Oort, Inge

AU - Yamoah, Kosj

AU - Ye, Dingwei

AU - Zapatero, Almudena

AU - Gillessen, Silke

AU - Omlin, Aurelius

N1 - Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2022/7

Y1 - 2022/7

N2 - Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

AB - Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. PATIENT SUMMARY: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients.

KW - Androgen Antagonists/therapeutic use

KW - COVID-19

KW - COVID-19 Vaccines

KW - Humans

KW - Male

KW - Pandemics/prevention & control

KW - Prostatic Neoplasms/pathology

U2 - 10.1016/j.eururo.2022.02.010

DO - 10.1016/j.eururo.2022.02.010

M3 - SCORING: Journal article

C2 - 35393158

VL - 82

SP - 6

EP - 11

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 1

ER -